## SECTION A — HUMAN-READABLE FULL REPORT (ARBITER-CONSOLIDATED)

### 1) Extracted key clinical data (case_bundle only; discrepancies resolved)

**Patient baseline**
- **Age/Sex:** 79-year-old woman.
- **Indication for therapy:** Facial neuralgia.
- **Past liver/biliary disease:** None (“no past history of disease of the liver or biliary tract”).
- **Transfusion history:** None (“never received a blood transfusion”).
- **Alcohol / pregnancy:** Not reported.

**Drug exposure history**
- **Suspected drug:** **Carbamazepine**
  - **Dose:** 200 mg daily.
  - **Start date:** **May 2, 1984**.
  - **Stop date:** **June 25, 1984** (admission day; “all the drugs were interrupted”).
  - **Rechallenge:** Not performed / not reported.

- **Concomitant drugs**
  - **Clobazepam:** started May 2, 1984; stopped June 25, 1984; later **readministered without interfering with recovery**.
  - **Vincamine:** taken for several years; stopped June 25, 1984; later **readministered without interfering with recovery**.

**Clinical course**
- **June 2, 1984:** itching begins.
- **June 24, 1984:** jaundice appears.
- **June 25, 1984:** admission; mild fever on exam; all drugs stopped.
- **Outcome:** clinical manifestations disappeared within **2 weeks**; liver tests and eosinophils returned to normal within **3 months**. No biliary tract disease evident one year after recovery (December 1985).

**Laboratory data at admission (June 25, 1984)**
- **Total bilirubin:** 113 µmol/L.
- **ALT:** 91 U/L (ULN 45) → **2.02 × ULN**.
- **ALP:** 25 U (ULN 5) → **5.0 × ULN**.
- **GGT:** 390 U (ULN 40).
- **WBC/eosinophils:** WBC 14,700/mm³ with 54% eosinophils (marked eosinophilia; later narrative mentions eosinophils reached 8,500/mm³).

**Imaging / histology**
- **Ultrasound:** liver and biliary tract normal.
- **Liver biopsy:** acute cholangitis-type injury with bile duct epithelial injury and cholestasis; no granuloma; only scarce necrotic hepatocytes.

**Alternative causes evaluated (as documented)**
- **Viral hepatitis:** HBsAg negative; anti-HBs absent; anti-HBc absent; anti-HAV IgM absent. (No data provided for HCV/HEV/EBV/CMV.)
- **Autoimmune markers:** AMA absent; SMA absent; anti-endoplasmic reticulum antibodies absent; ANA present 1:100 (nonspecific).
- **Parasitic:** fascioliasis and echinococcosis serologies negative.
- **Biliary obstruction:** ultrasound normal; later follow-up without biliary tract disease.

---

### 2) R-ratio calculation and injury pattern determination (discrepancies resolved)

Using admission values with stated ULN:

- ALT/ULN = 91/45 = **2.02**
- ALP/ULN = 25/5 = **5.00**

\[
R = \frac{2.02}{5.00} = 0.404
\]

**R = 0.40 → Cholestatic pattern (R ≤ 2).**  
Apply **RUCAM cholestatic/mixed** table.

---

### 3) RUCAM scoring (cholestatic/mixed) — final arbiter scores

**Causality assessed for:** Carbamazepine.

#### Item 1 — Time to onset from drug start
- Start May 2 → itching June 2 (~31 days) and jaundice June 24 (~53 days).
- Compatible with cholestatic DILI latency (5–90 days).
- **Final score: +2**

#### Item 2 — Course after cessation (dechallenge)
- All drugs stopped June 25.
- Clinical manifestations resolved within 2 weeks; **liver function tests returned to normal within 3 months (~90 days)**.
- Although serial ALP/bilirubin values are not provided, normalization within 90 days is a strong compatible cholestatic dechallenge within the 180-day window used in RUCAM cholestatic/mixed.
- **Final score: +2**

#### Item 3 — Risk factors
- Age 79 (>55).
- Alcohol not reported.
- **Final score: +1**

#### Item 4 — Concomitant drugs
- Clobazepam (started same day) and long-term vincamine were co-administered and stopped at admission.
- **Both were readministered without interfering with recovery**, arguing against them as causes in this episode.
- **Final score: 0** (no penalty)

#### Item 5 — Non-drug causes excluded
- Documented exclusions: HAV IgM negative; HBV markers negative; ultrasound normal (no obstruction); parasites negative; autoimmune markers largely negative (ANA low-titer only); follow-up without biliary tract disease.
- Missing in case_bundle: HCV/HEV/EBV/CMV testing; alcohol history; ischemic evaluation.
- Under strict RUCAM application to the provided evidence, this is **not “all causes reasonably excluded”**; it is **partial exclusion**.
- **Final score: +1**

#### Item 6 — Known hepatotoxicity of the suspected drug
- Carbamazepine is a well-established cause of DILI, including cholestatic/cholangitis-type injury, and the report itself cites prior cases.
- **Final score: +2**

#### Item 7 — Re-exposure (rechallenge)
- No carbamazepine rechallenge.
- **Final score: 0**

---

### 4) Final RUCAM score and causality category (consolidated)

**Total score = 2 + 2 + 1 + 0 + 1 + 2 + 0 = 8**

**RUCAM category:** **Probable** (6–8).

**Final decision:** **Probable carbamazepine-induced cholestatic liver injury** (acute cholangitis phenotype with eosinophilia), based strictly on the case_bundle.

---

## SECTION B — RUCAM SCORING TABLE (FINAL)

| RUCAM Item | Final Score | Evidence (case_bundle) |
|---|---:|---|
| Time to onset | +2 | Carbamazepine started May 2; itching June 2; jaundice June 24 (compatible 5–90 days). |
| Course after cessation | +2 | All drugs stopped June 25; symptoms resolved within 2 weeks; liver tests normalized within 3 months (~90 days). |
| Risk factors | +1 | Age 79 (>55). |
| Concomitant drugs | 0 | Vincamine long-term; clobazepam started May 2; both later readministered without interfering with recovery. |
| Non-drug causes excluded | +1 | HBV/HAV negative; ultrasound normal; parasites negative; autoimmune markers largely negative; but HCV/HEV/EBV/CMV and alcohol/ischemia not documented. |
| Known hepatotoxicity | +2 | Carbamazepine is a published/established hepatotoxin; report discusses known injury patterns. |
| Rechallenge | 0 | No carbamazepine readministration. |
| **Total** | **8** | **Category: Probable** |

---

## SECTION C — MACHINE-READABLE JSON (FINAL)

```json
{
  "injury_pattern": "cholestatic",
  "R_ratio": 0.404,
  "rucam_scores": {
    "time_to_onset": 2,
    "course": 2,
    "risk_factors": 1,
    "concomitant_drugs": 0,
    "other_causes_excluded": 1,
    "known_hepatotoxicity": 2,
    "rechallenge": 0
  },
  "total_score": 8,
  "category": "Probable"
}
```

---

## SECTION D — ARBITER JUSTIFICATION (DISCREPANCY RESOLUTION)

### 1) Extracted facts disagreements
- **No material disagreements** between GPT-5.2 and Gemini on core dates, labs, imaging, biopsy, or drug exposure. Both correctly identify: start May 2; itching June 2; jaundice June 24; stop June 25; ALT 91 (ULN 45); ALP 25 (ULN 5); bilirubin 113; ultrasound normal; biopsy cholangitis-type; vincamine/clobazepam readministered without issue.

### 2) R-ratio and injury pattern
- **Both reports agree** on R-ratio (~0.40) and **cholestatic** pattern. Arbiter confirms using only provided ALT/ALP and ULN values: **R = 0.404**, cholestatic.

### 3) RUCAM item-by-item discrepancies and final choices

**Item 1 (Time to onset):**  
- GPT: +2; Gemini: +2.  
- **Arbiter:** +2 (31–53 days fits 5–90 day window).

**Item 2 (Course):**  
- GPT: +2 (qualitative normalization by 3 months); Gemini: +2 (asserts ≥50% fall within 180 days).  
- **Arbiter:** +2, but justification anchored to case_bundle: normalization within ~90 days is compatible with a positive cholestatic dechallenge within 180 days, even though exact % fall at specific timepoints is not numerically documented.

**Item 3 (Risk factors):**  
- GPT: +1; Gemini: +1.  
- **Arbiter:** +1 (age >55).

**Item 4 (Concomitant drugs):**  
- GPT: 0; Gemini: 0.  
- **Arbiter:** 0 because negative re-administration of vincamine and clobazepam (“did not interfere with recovery”) argues against them; no evidence they caused the event.

**Item 5 (Non-drug causes excluded):**  
- **Disagreement:** GPT assigns **+2**; Gemini assigns **+1**.  
- **Arbiter decision: +1** strictly per case_bundle and RUCAM rules: while HBV/HAV, obstruction (US), parasites, and several autoimmune markers were addressed, **HCV/HEV and other viral causes are not documented**, and alcohol/ischemic causes are not discussed. Therefore, the evidence supports **partial** rather than complete exclusion.

**Item 6 (Known hepatotoxicity):**  
- GPT: +2; Gemini: +2.  
- **Arbiter:** +2 (well-known, published carbamazepine DILI; supported by report discussion).

**Item 7 (Rechallenge):**  
- GPT: 0; Gemini: 0.  
- **Arbiter:** 0 (no carbamazepine rechallenge).

### 4) Final total score/category discrepancy
- GPT total **9 (Highly probable)** vs Gemini total **8 (Probable)** driven solely by Item 5.  
- With Item 5 fixed at **+1**, **final total = 8 → Probable**, which is the arbiter-consolidated RUCAM outcome based strictly on the case_bundle evidence.